Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Fresenius SE & Co. KGaA    FRE   DE0005785604

FRESENIUS SE & CO. KGAA

(FRE)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Fresenius SE Backs Guidance After Sales, Operating Profit Rose in 1Q

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/02/2019 | 01:31am EDT

By Donato Paolo Mancini

Fresenius SE & Co. KGaA (FRE.XE) on Thursday backed its group guidance after first-quarter sales and operating profit edged higher.

Net income was 465 million euros ($511 million), flat in constant currencies. Operating profit edger higher to EUR1.11 billion, while sales grew 5% to EUR8.52 billion.

The company affirmed its group guidance, despite expected earnings dilution from the acquisition of NxStage.

At Fresenius Medical Care, the company's dialysis division, net profit, operating profit and sales all grew on-year.

Net profit was EUR318 million, operating profit was EUR551 million and sales gained 6% to EUR4.13 billion.

Write to Donato Paolo Mancini at donatopaolo.mancini@dowjones.com; @donatopmancini

Stocks mentioned in the article
ChangeLast1st jan.
E.ON SE 0.75% 8.997 Delayed Quote.3.51%
FRESENIUS MEDICAL CARE AG & CO. KGAA 0.22% 63.3 Delayed Quote.11.62%
FRESENIUS SE & CO. KGAA -0.65% 44.76 Delayed Quote.6.50%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on FRESENIUS SE & CO. KGAA
09/16FRESENIUS : 2020 DRG inflator for German hospitals set at 3.66%
PU
09/15Fresenius drops possible sale of blood transfusion unit - spokesman
RE
09/13FRESENIUS SE & CO. KGAA : Release according to Article 40, Section 1 of the WpHG..
EQ
09/11FRESENIUS : Helios launches digital portal for patients
PU
09/09FRESENIUS : Medical Care's publishes annual medical report
PU
09/06FRESENIUS : Medical Care builds new laboratory in Mississippi
PU
09/05Fresenius Medical Care to Invest in Its Stem-Cell Subsidiary Unicyte
DJ
09/05FRESENIUS : Medical Care invests EUR 60 million in Unicyte
PU
09/03Fresenius Helios Acquires Two Hospitals in Colombia
DJ
08/30FRESENIUS : Kabi launches IV Drug in the U.S.
PU
More news
Financials (EUR)
Sales 2019 35 385 M
EBIT 2019 4 647 M
Net income 2019 1 839 M
Debt 2019 20 938 M
Yield 2019 1,76%
P/E ratio 2019 13,7x
P/E ratio 2020 12,5x
EV / Sales2019 1,30x
EV / Sales2020 1,15x
Capitalization 25 145 M
Chart FRESENIUS SE & CO. KGAA
Duration : Period :
Fresenius SE & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS SE & CO. KGAA
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 56,68  €
Last Close Price 45,26  €
Spread / Highest target 65,3%
Spread / Average Target 25,2%
Spread / Lowest Target -28,3%
EPS Revisions
Managers
NameTitle
Stephan Sturm President & Chief Executive Officer
Gerd Krick Chairman-Supervisory Board
Rachel Clare Empey Chief Financial Officer
Niko Stumpfögger Deputy Chairman-Supervisory Board
Klaus-Peter Müller Member-Supervisory Board
Sector and Competitors